Ignyta (RXDX) Announces Second Quarter 2014 Company Highlights And Financial Results
8/13/2014 7:55:49 AM
SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, today announced company highlights and financial results for the second quarter ended June 30, 2014.
“Since the beginning of the second quarter, we have continued to make solid progress toward our goal of becoming a leading precision medicine biotechnology company by developing targeted therapeutics for cancer patients,” said Jonathan Lim, M.D., Chairman and CEO of Ignyta. “We initiated our STARTRK-1 clinical trial of RXDX-101, in which leading cancer centers in the U.S., Europe and Asia will utilize a continuous daily dosing regimen in treating patients with advanced, metastatic solid tumors, and we bolstered our pipeline with the addition of our RXDX-103 and RXDX-104 development programs. We also announced promising data at ASCO from our ongoing, Italy-based ALKA-372-001 Phase I clinical trial of RXDX-101, and we continued to expand our team with incredibly talented people.”
Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available.
Help employers find you! Check out all the jobs and post your resume.
comments powered by